BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 9738665)

  • 1. Fas ligand (gld)- and Fas (lpr)-deficient mice do not show alterations in the extravasation or apoptosis of inflammatory neutrophils.
    Fecho K; Cohen PL
    J Leukoc Biol; 1998 Sep; 64(3):373-83. PubMed ID: 9738665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mice deficient in fas ligand (gld) or fas (lpr) show few alterations in granulopoiesis.
    Fecho K; Bentley SA; Cohen PL
    Cell Immunol; 1998 Aug; 188(1):19-32. PubMed ID: 9743554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fas-mediated cytotoxicity is not required for rejection of murine nonvascularized heterotopic cardiac allografts.
    Djamali A; Odorico JS
    Transplantation; 1998 Dec; 66(12):1793-801. PubMed ID: 9884278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fas/Fas ligand-mediated apoptosis promotes hypersensitivity pneumonitis in mice by enhancing maturation of dendritic cells.
    Hwang SJ; Kim HS; Chung DH
    Am J Respir Crit Care Med; 2010 Jun; 181(11):1250-61. PubMed ID: 20194815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fas/Apo-1 (CD95)-mediated apoptosis of neutrophils with Fas ligand (CD95L)-expressing tumors is crucial for induction of inflammation by neutrophilic polymorphonuclear leukocytes associated with antitumor immunity.
    Shimizu M; Fontana A; Takeda Y; Yoshimoto T; Tsubura A; Matsuzawa A
    Cell Immunol; 2001 Jan; 207(1):41-8. PubMed ID: 11161452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphocytes with aberrant expression of Fas or Fas ligand attenuate immune bone marrow failure in a mouse model.
    Omokaro SO; Desierto MJ; Eckhaus MA; Ellison FM; Chen J; Young NS
    J Immunol; 2009 Mar; 182(6):3414-22. PubMed ID: 19265119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defective Fas ligand-mediated apoptosis predisposes to development of a chronic erosive arthritis subsequent to Mycoplasma pulmonis infection.
    Hsu HC; Zhang HG; Song GG; Xie J; Liu D; Yang PA; Fleck M; Wintersberger W; Zhou T; Edwards CK; Mountz JD
    Arthritis Rheum; 2001 Sep; 44(9):2146-59. PubMed ID: 11592380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of chronic sialadenitis in a murine model of Sjögren's syndrome by local fasL gene transfer.
    Fleck M; Zhang HG; Kern ER; Hsu HC; Müller-Ladner U; Mountz JD
    Arthritis Rheum; 2001 Apr; 44(4):964-73. PubMed ID: 11315936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fas-FasL interaction involved in pathogenesis of ocular toxoplasmosis in mice.
    Hu MS; Schwartzman JD; Yeaman GR; Collins J; Seguin R; Khan IA; Kasper LH
    Infect Immun; 1999 Feb; 67(2):928-35. PubMed ID: 9916110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Nef-mediated AIDS-like disease of CD4C/human immunodeficiency virus transgenic mice is associated with increased Fas/FasL expression on T cells and T-cell death but is not prevented in Fas-, FasL-, tumor necrosis factor receptor 1-, or interleukin-1beta-converting enzyme-deficient or Bcl2-expressing transgenic mice.
    Priceputu E; Rodrigue I; Chrobak P; Poudrier J; Mak TW; Hanna Z; Hu C; Kay DG; Jolicoeur P
    J Virol; 2005 May; 79(10):6377-91. PubMed ID: 15858021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fas- or FasL-deficient mice display an increased sensitivity to nitrobenzene-induced testicular germ cell apoptosis.
    Richburg JH; Nañez A
    Toxicol Lett; 2003 Mar; 139(1):1-10. PubMed ID: 12595153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Fas-Fas ligand interactions in 2,3,7,8-tetrachlorodibenzo- p-dioxin (TCDD)-induced immunotoxicity: increased resistance of thymocytes from Fas-deficient (lpr) and Fas ligand-defective (gld) mice to TCDD-induced toxicity.
    Kamath AB; Camacho I; Nagarkatti PS; Nagarkatti M
    Toxicol Appl Pharmacol; 1999 Oct; 160(2):141-55. PubMed ID: 10527913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal tubular epithelial cell apoptosis by Fas-FasL-dependent self-injury can augment renal allograft injury.
    Du C; Guan Q; Yin Z; Masterson M; Zhong R; Jevnikar AM
    Transplant Proc; 2003 Nov; 35(7):2481-2. PubMed ID: 14611992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological and pathological consequences of mutations in both Fas and Fas ligand.
    Weintraub JP; Godfrey V; Wolthusen PA; Cheek RL; Eisenberg RA; Cohen PL
    Cell Immunol; 1998 May; 186(1):8-17. PubMed ID: 9637760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased retinal neovascularization in Fas ligand-deficient mice.
    Davies MH; Eubanks JP; Powers MR
    Invest Ophthalmol Vis Sci; 2003 Jul; 44(7):3202-10. PubMed ID: 12824272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of Fas-FasL in the development and treatment of ischemic retinopathy.
    Barreiro R; Schadlu R; Herndon J; Kaplan HJ; Ferguson TA
    Invest Ophthalmol Vis Sci; 2003 Mar; 44(3):1282-6. PubMed ID: 12601060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FasL-Fas interactions regulate neovascularization in the cornea.
    Stuart PM; Pan F; Plambeck S; Ferguson TA
    Invest Ophthalmol Vis Sci; 2003 Jan; 44(1):93-8. PubMed ID: 12506060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The critical role of Fas-Fas ligand interaction in donor-specific transfusion-induced tolerance to H-Y antigen.
    Minagawa R; Okano S; Tomita Y; Kishihara K; Yamada H; Nomoto K; Shimada M; Maehara Y; Sugimachi K; Yoshikai Y; Nomoto K
    Transplantation; 2004 Sep; 78(6):799-806. PubMed ID: 15385797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fas and Fas ligand expressed on cells of the immune system, not on the target tissue, control induction of experimental autoimmune uveitis.
    Wahlsten JL; Gitchell HL; Chan CC; Wiggert B; Caspi RR
    J Immunol; 2000 Nov; 165(10):5480-6. PubMed ID: 11067900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Up-regulation of Fas and the costimulatory molecules B7-1 and B7-2 on peripheral lymphocytes in autoimmune B6/gld mice.
    Weintraub JP; Eisenberg RA; Cohen PL
    J Immunol; 1997 Oct; 159(8):4117-26. PubMed ID: 9379003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.